FDA Accepts Ultragenyx's BLA for Sanfilippo Syndrome Gene Therapy

The FDA has accepted Ultragenyx's Biologics License Application (BLA) for UX111, a gene therapy designed to treat Sanfilippo Syndrome. This acceptance moves the therapy closer to potential regulatory approval.